Sentences with phrase «in prostate cancer research»

Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta.

While nomograms are common in prostate cancer research, the one developed by the Fred Hutch and UW researchers is the first to determine the likelihood of over-diagnosis on an individual level, said Ruth Etzioni, Ph.D., the paper's senior author.

Not exact matches

Prior to joining the OCC, Rossi most recently served as President and CEO of Prostate Cancer Canada where he helped to advance the research, advocacy, education and awareness of the most common cancer iCancer Canada where he helped to advance the research, advocacy, education and awareness of the most common cancer icancer in men.

3) Reduced Risk Of Some Cancers — Although the connection is not fully understood, a significant body of research has linked high levels of calcium in the blood with fatal prostate cancer in men.

For instance, research has shown that combining cauliflower with curcumin (the active compound in the spice turmeric) may help prevent and treat prostate cancer.1

Only breast cancer and prostate cancer seem to have received much attention in the research world in connection with pumpkin seed intake, and much of that attention has been limited to the lignan content of pumpkin seeds.

To some extent, this same focus on lignans has occurred in research on prostate cancer as well.

She is a mentor in Collegiate Connections, a member of Love Your Melon CWRU, and is working on a prostate cancer research project at Case School of Medicine.

Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports.

Speaking about the research, Dr Hawkins said: «We were really surprised that loss of PTEN caused such a dramatic increase in PI (3,4) P2 in our mouse model of prostate cancer.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tCancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tcancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.

The findings could shake up prostate cancer research, providing targets for treatment, diagnosis and monitoring of one of the most prevalent cancers in the west.

Dr Emma Turner, a Cancer Research UK scientist at the University of Bristol and co-author of the study, said: «Prostate cancer is the second most common cause of cancer death in men in tCancer Research UK scientist at the University of Bristol and co-author of the study, said: «Prostate cancer is the second most common cause of cancer death in men in tcancer is the second most common cause of cancer death in men in tcancer death in men in the UK.

«We show that high dietary saturated fat content is associated with increased prostate cancer aggressiveness,» said Emma H. Allott, PhD, a research assistant professor in the UNC Gillings School of Global Public Health.

The findings could shake up prostate cancer research, providing targets for treatment of one of the most prevalent cancers in the west.

Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment / prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld - Tanenbaum Research Institute.

«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»

A man's blood group can affect the chance of a recurrence of prostate cancer after surgery, according to new research, which was presented at the European Association of Urology congress in Stockholm.

In 2009 the nongovernmental Institute of Medicine (IOM) released a list of 100 disorders, including lower back pain, atrial fibrillation, and early prostate cancer, that it says require research analyzing which treatments work best for different groups of patients.

David Agus, the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patCancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patcancer patients.

First, the research demonstrates that RB status can be tracked using cell - free DNA samples, an approach referred to as «liquid biopsy,» in prostate cancer patient samples.

Published in the journal Cancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of theCancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of thecancer will spread from the prostate tumour to other parts of the body.

Besides working at IBM's Thomas J. Watson Research Center in Yorktown Heights, New York, Meyer heads something called the DREAM challenges, contests that ask teams of computer scientists to solve outstanding biomedical problems, such as predicting the outcome of prostate cancer treatment based on clinical variables or detecting breast cancer from mammogram data.

«The phi test helps physicians distinguish prostate cancer from benign conditions by utilizing three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels,» said Kevin Slawin, MD, director, Vanguard Urologic Institute at Memorial Hermann Medical Group, clinical professor of Urology at Baylor College of Medicine and director of Urology, Memorial Hermann Hospital ‐ Texas Medical Center, who performed some of the key research that led to the development of the phi test and who also began using the test in February.

«These findings give us reason to rethink how we manage prostate cancer in men with known heart disease,» said Anthony D'Amico, MD, lead author of the research paper and chief of genitourinary radiation oncology at Brigham and Women's Hospital..

A drug used to treat men with late - stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (Cancer Institute at Oregon Health & Science University (OHSU).

A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer.

The current authors evaluated the effects of ADT on mental and emotional well - being in men diagnosed with localized prostate cancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the Unitedprostate cancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United Scancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United SCancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the UnitedProstate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United States.

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine.

Dr Wells» team has previously published research on the importance of PAK4 in other types of cancer, including prostate, breast and melanoma.

This research, published in the March 3 edition of PLOS ONE, provides the first evidence that urinary BPA levels may help predict prostate cancer and that disruption of a cell duplication cycle through exposure to low - dose BPA may cause cancer development in the prostate.

A research team led by Jeanne Mager Stellman of the Mailman School of Public Health at Columbia University reported in April that the herbicides used to defoliate battle zones contained two to four times the previously reported levels of dioxin, a poison linked to a high incidence of prostate cancer, diabetes, birth defects, and other ailments among American veterans, the Vietnamese, and their descendants.

The research teams, led by Nima Sharifi, M.D., of the Cleveland Clinic Lerner Research Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapresearch teams, led by Nima Sharifi, M.D., of the Cleveland Clinic Lerner Research Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapResearch Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapy (ADT).

A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Jonathan Wright at Fred Hutchinson Cancer Research Center in Seattle and colleagues asked 3000 men — around half of whom had prostate cancer — if they had been circumcised and when they first haCancer Research Center in Seattle and colleagues asked 3000 men — around half of whom had prostate cancer — if they had been circumcised and when they first hacancer — if they had been circumcised and when they first had sex.

But the Cedars - Sinai research suggests that some prostate cancer patients may not receive needed treatments in a timely way.

New research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.

Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer cells could also be used as a way to guide treatments to the cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liresearch presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research Institute (NCRI) Cancer Conference in LiResearch Institute (NCRI) Cancer Conference in LiveCancer Conference in Liverpool.

In terms of diagnostics, it has six tests on the market, based on research in Iceland, that aim to measure risk of diseases such as heart attack and prostate canceIn terms of diagnostics, it has six tests on the market, based on research in Iceland, that aim to measure risk of diseases such as heart attack and prostate cancein Iceland, that aim to measure risk of diseases such as heart attack and prostate cancer.

Recently published in the journal eLife and featured in a poster session at this year's American Association for Cancer Research (AACR) annual meeting, preclinical experiments show for the first time that PLK1 promotes the migration of prostate cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition Cancer Research (AACR) annual meeting, preclinical experiments show for the first time that PLK1 promotes the migration of prostate cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition (EMT).

«After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,» says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.

Recent years have seen extensive research on the genetics of prostate cancer, with over a hundred mutations identified, however most of these are only present in a small number of men.

The new research could lead to a change in the way treatment decisions are made for prostate cancer patients.

«Our research provides the first direct evidence that exposure to BPA during development, at the levels we see in our day - to - day lives, increases the risk for prostate cancer in human prostate tissue,» Prins said.

The study, which appears online June 1, 2015 in the journal Cancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thCancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thcancer in the U.S.

Each man needs to work within his own limits, and each has different needs nutritionally,» said Focht, who wants to replicate the research with about 200 prostate cancer patients to see if the findings in this small pilot study hold true.

In addition, research continues to uncover new clues to identify which men are at highest risk of aggressive prostate cancer and could most benefit from screening and treatment.

Dr. Timmerman, who holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and proCancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and procancer in the lung, liver, spine, and prostate.

Worldwide, prostate cancer is the second-most common cancer in men, according to the World Cancer Research Fund Internatcancer is the second-most common cancer in men, according to the World Cancer Research Fund Internatcancer in men, according to the World Cancer Research Fund InternatCancer Research Fund International.